Drug Approval | December 23, 2025
Novo Nordisk’s Wegovy pill approved in US as first oral GLP-1 for weight management
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
Full approval will depend on verification of clinical benefit in a confirmatory trial
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
Subscribe To Our Newsletter & Stay Updated
